Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment
US12403146B2 · kind B2 · utility
0Cited by
46References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 30, 2020 |
| Grant date | Sep 2, 2025 |
| Priority date | — |
| Expiry date | Oct 29, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/44
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention features new testosterone undecanoate (TU) dosing regimens, e.g., for testosterone replacement therapy. The TU may be formulated with phytosterols or phytosterol esters.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.